Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Second Quarter 2024 Financial Results
and Business Updates
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
July 26, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
June 14, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Three Clinical Data Updates on obe-cel at EHA
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
May 31, 2024 08:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 17, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
April 02, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL
Autolus Therapeutics Announces Changes to its Board of Directors
April 01, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 14, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Autolus Therapeutics announces publication in Nature Communications
February 22, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces publication in Nature Communications
Autolus Announces Pricing of Underwritten Offering
February 08, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Announces Pricing of Underwritten Offering